A detailed history of Commonwealth Equity Services, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 5,303 shares of ALNY stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,303
Previous 5,752 7.81%
Holding current value
$1.29 Million
Previous $1.4 Million 4.29%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$233.81 - $287.01 $104,980 - $128,867
-449 Reduced 7.81%
5,303 $1.46 Million
Q2 2024

Jul 31, 2024

BUY
$143.31 - $247.0 $22,642 - $39,026
158 Added 2.82%
5,752 $1.4 Million
Q1 2024

Apr 29, 2024

BUY
$146.51 - $198.2 $199,986 - $270,543
1,365 Added 32.28%
5,594 $836,000
Q4 2023

Feb 06, 2024

SELL
$151.41 - $196.57 $21,651 - $28,109
-143 Reduced 3.27%
4,229 $809,000
Q3 2023

Oct 23, 2023

BUY
$170.77 - $211.65 $61,989 - $76,828
363 Added 9.05%
4,372 $774,000
Q2 2023

Aug 10, 2023

BUY
$185.01 - $212.05 $64,383 - $73,793
348 Added 9.51%
4,009 $761,000
Q1 2023

May 11, 2023

SELL
$182.66 - $235.53 $282,392 - $364,129
-1,546 Reduced 29.69%
3,661 $733,000
Q4 2022

Feb 07, 2023

BUY
$185.53 - $241.31 $80,334 - $104,487
433 Added 9.07%
5,207 $1.24 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $27,430 - $45,936
198 Added 4.33%
4,774 $955,000
Q2 2022

Jul 19, 2022

SELL
$120.42 - $169.29 $53,225 - $74,826
-442 Reduced 8.81%
4,576 $667,000
Q1 2022

May 04, 2022

SELL
$127.18 - $173.91 $24,545 - $33,564
-193 Reduced 3.7%
5,018 $819,000
Q4 2021

Jan 31, 2022

BUY
$159.56 - $209.29 $150,305 - $197,151
942 Added 22.07%
5,211 $883,000
Q3 2021

Oct 29, 2021

SELL
$169.75 - $207.73 $17,484 - $21,396
-103 Reduced 2.36%
4,269 $806,000
Q2 2021

Aug 11, 2021

SELL
$128.63 - $176.89 $57,111 - $78,539
-444 Reduced 9.22%
4,372 $741,000
Q1 2021

May 04, 2021

BUY
$126.83 - $175.69 $60,371 - $83,628
476 Added 10.97%
4,816 $679,000
Q4 2020

Feb 11, 2021

SELL
$122.97 - $147.0 $860 - $1,029
-7 Reduced 0.16%
4,340 $564,000
Q3 2020

Nov 05, 2020

BUY
$121.19 - $165.49 $16,118 - $22,010
133 Added 3.16%
4,347 $632,000
Q2 2020

Aug 12, 2020

BUY
$104.21 - $156.44 $8,753 - $13,140
84 Added 2.03%
4,214 $624,000
Q1 2020

May 11, 2020

SELL
$93.12 - $133.99 $136,886 - $196,965
-1,470 Reduced 26.25%
4,130 $449,000
Q4 2019

Feb 05, 2020

SELL
$74.51 - $124.23 $108,710 - $181,251
-1,459 Reduced 20.67%
5,600 $644,000
Q3 2019

Oct 30, 2019

SELL
$70.9 - $87.82 $2,623 - $3,249
-37 Reduced 0.52%
7,059 $567,000
Q2 2019

Jul 19, 2019

BUY
$65.86 - $92.79 $5,005 - $7,052
76 Added 1.08%
7,096 $514,000
Q1 2019

May 13, 2019

SELL
$72.76 - $93.45 $149,230 - $191,665
-2,051 Reduced 22.61%
7,020 $656,000
Q4 2018

Feb 11, 2019

BUY
$62.67 - $88.33 $363,611 - $512,490
5,802 Added 177.49%
9,071 $661,000
Q3 2018

Nov 06, 2018

BUY
$87.52 - $122.67 $18,029 - $25,270
206 Added 6.73%
3,269 $286,000
Q2 2018

Jul 31, 2018

BUY
$88.31 - $107.8 $8,831 - $10,780
100 Added 3.37%
3,063 $302,000
Q1 2018

May 14, 2018

SELL
$115.92 - $148.54 $337,327 - $432,251
-2,910 Reduced 49.55%
2,963 $352,000
Q4 2017

Feb 12, 2018

BUY
$114.49 - $139.98 $672,399 - $822,102
5,873
5,873 $746,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.